BRICS intensify pharma tie-ups to promote innovation
This article was originally published in SRA
Executive Summary
Tuberculosis, HIV/AIDS and now Ebola: the developing world is facing a string of public health challenges, while on the other hand, the cost of innovative new therapies such as hepatitis C treatment Sovaldi (sofosbuvir) is so high that few in the third world can afford them.